PharmaTher To Raise $10.0 Million Via Institutional Investor Financing

PharmaTher Holdings (CSE: PHRM) this morning indicated that the company has secured a financing with institutional investors. The firm will be raising C$10.0 million via a financing conducted exclusively by H.C. Wainwright.

The financing will see the company sell a total of 15.6 million units of the company price at $0.64 per each, with each unit containing one common share and one common share purchase warrant. Each warrant, priced at $0.80 per share, is valid for a period of five years from the date of issuance.

Proceeds from the financing are to be used for the development of the firms microneedle patch, its ketamine product, and general working capital.

The financing is currently slated to close September 28, 2021.

PharmaTher Holdings last traded at $0.80 on the CSE.


Information for this briefing was found via Sedar and the companies mentioned. PharmaTher Holdings is a former client of The Deep Dive. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

2026 Could Be Gold’s Biggest Year Yet!? | Ryan King – Equinox Gold

Gold Is Screaming Higher While Currencies Burn | Simon Ridgway – Rackla Metals

We Have the Highest-Grade Antimony Deposit in North America!? | Jim Atkinson -Antimony Resources

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

PharmaTher Applies For Pre-IND Meeting With US FDA For Ketabet

PharmaTher Holdings (CSE: PHRM) this morning announced that it continues to push forward with the...

Tuesday, June 15, 2021, 08:14:25 AM

PharmaTher: Maxim Initiates Coverage With US$1.50 Price Target

PharmaTher Holdings (CSE: PHRM) had its first initiation report that came out on June 28th....

Wednesday, June 30, 2021, 02:38:00 PM

PharmaTher Files Patent For Use Of Ketamine In Type 2 Diabetes, Obesity

PharmaTher Holdings (CSE: PHRM) has expanded its patent portfolio. The company this morning announced the...

Tuesday, April 27, 2021, 07:54:44 AM

PharmaTher Acquires Exclusive Rights To Patented Ketamine Formulation

PharmaTher Inc (CSE: PHRM) has entered into an exclusive worldwide license agreement for the development...

Tuesday, January 19, 2021, 09:24:20 AM

Pharmather Files For Orphan Drug Status For Use Of Ketamine Against Postherpetic Neuralgia

Pharmather Inc (CSE: PHRM) this morning announced that it has filed for orphan drug status...

Tuesday, October 27, 2020, 08:42:25 AM